IRVINE, Calif. - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a biotechnology company with a market capitalization of $284.54 million and a remarkable 170% stock return over the past year according to ...
We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...